Yang Lihong, Yu Xuehui
Department of Nursing, Medical College of ChiFeng University, Chifeng, Inner Mongolia 024000, China.
Department of Orthopedic, The Central Hospital of Ningcheng, Chifeng, Inner Mongolia 024200, China.
Acta Biochim Pol. 2021 Sep 2;68(4):647-652. doi: 10.18388/abp.2020_5531.
The currently used anticancer drugs against breast cancer possess serious side effects, have limited efficacy, and often lead to recurrence of the malignancy. The main aim of this research was to investigate the anticancer potential of Girinimbine, a naturally occurring carbazole alkaloid, against ER-negative breast cancer cells (MDA-MB-453) along with its effects on cell migration and invasion, apoptosis, and MEK/ERK/STAT3 pathway. MTT assay was used to evaluate antiproliferative effects of Girinimbine while a clonogenic assay was used to study cell colony formation. Transwell migration and invasion assays were involved to study its effects on cell migration and invasion. Fluorescence microscopy using acridine orange/ethidium bromide was used to study apoptotic effects of girinimbine which was quantified by annexin v-FITC assay. Effects of girinimbine on MEK/ERK and STAT3 signalling pathways were evaluated by western blot assay. Results showed that girinimbine exhibited dose-dependent as well as time-dependent antiproliferative effects in MDA-MB-453 cells along with strongly inhibiting the cell colony potency of these cancerous cells. Girinimbine can inhibit both cancer cell migration as well as invasion. Girinimbine has induced potent chromatin condensation and nuclear fragmentation. The percentage of both early and late apoptotic cells increased significantly after girinimbine exposure. The anticancer effects of girinimbine were shown to be mediated via inhibition of the MEK/ERK as well as STAT3 signalling pathways. In conclusion, it may be proposed that girinimbine could be a promising anticancer agent against breast cancer, provided further in-depth studies are carried out.
目前用于治疗乳腺癌的抗癌药物具有严重的副作用,疗效有限,且常常导致恶性肿瘤复发。本研究的主要目的是探究一种天然咔唑生物碱——柯里拉京,对雌激素受体阴性乳腺癌细胞(MDA-MB-453)的抗癌潜力,以及其对细胞迁移、侵袭、凋亡和MEK/ERK/STAT3信号通路的影响。采用MTT法评估柯里拉京的抗增殖作用,同时使用克隆形成试验研究细胞集落形成。采用Transwell迁移和侵袭试验研究其对细胞迁移和侵袭的影响。使用吖啶橙/溴化乙锭荧光显微镜研究柯里拉京的凋亡作用,并通过膜联蛋白v-FITC试验进行定量分析。通过蛋白质免疫印迹法评估柯里拉京对MEK/ERK和STAT3信号通路的影响。结果表明,柯里拉京在MDA-MB-453细胞中表现出剂量依赖性和时间依赖性的抗增殖作用,同时强烈抑制这些癌细胞的细胞集落形成能力。柯里拉京能够抑制癌细胞的迁移和侵袭。柯里拉京可诱导显著的染色质凝聚和核碎裂。柯里拉京处理后,早期和晚期凋亡细胞的百分比均显著增加。结果显示,柯里拉京的抗癌作用是通过抑制MEK/ERK以及STAT3信号通路介导的。总之,可以提出,柯里拉京可能是一种有前景的抗乳腺癌药物,但还需要进一步深入研究。